BackAlbany Molecular Research Overview

Albany Molecular Research Receivables

Albany Molecular Research's receivables is $140M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$139.34M
↑ 38.53% YoYΔ $38.75M vs prior year quarter

Peer trimmed avg / median

Loading

Albany Molecular Research Receivables History

Loading

Albany Molecular Research vs. peers: Receivables Comparison

Loading

Albany Molecular Research Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Albany Molecular Research (AMRI) FAQ

As of the most recent data (June 2017), AMRI shows a receivables of $140M. That compares with $100M in the prior-year period — up 38.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMRI's receivables is now $140M (was $100M) — a 38.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Albany Molecular Research is outperforming or lagging.

Tracking AMRI's receivables over time shows whether Albany Molecular Research is scaling, shrinking, or reshaping that part of the business. The current reading is $140M That compares with $100M in the prior-year period — up 38.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Albany Molecular Research's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $140M) with ownership activity and broader fundamentals.